2 weeks Ago By ABMN Staff
Matrix Private Capital Group LLC raised its stake in Novo Nordisk A/S ( NYSE:NVO – Free Report ) by 7.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,757 shares of the company’s stock after acquiring an additional 129 shares during the period.
Matrix Private Capital Group LLC’s holdings in Novo Nordisk A/S were worth $251,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors have also made changes to their positions in NVO. GQG Partners LLC boosted its position in shares of Novo Nordisk A/S by 654.
6% during the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock worth $466,485,000 after buying an additional 3,151,584 shares during the period. DSM Capital Partners LLC boosted its position in shares of Novo Nordisk A/S by 257,816.
0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after buying an additional 1,593,303 shares during the period. Capital International Investors boosted its position in shares of Novo Nordisk A/S by 22.
3% during the fourth quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock worth $736,121,000 after buying an additional 1,297,536 shares during the period. Acadian Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 1,300.
8% during the first quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock worth $159,703,000 after buying an additional 1,155,313 shares during the period. Finally, Price T Rowe Associates Inc.
MD boosted its position in shares of Novo Nordisk A/S by 10.6% during the first quarter. Price T Rowe Associates Inc.
MD now owns 8,589,222 shares of the company’s stock worth $1,102,857,000 after buying an additional 823,036 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.
Novo Nordisk A/S Price Performance NYSE NVO opened at $124.29 on Friday. The stock has a market capitalization of $557.
76 billion, a P/E ratio of 42.86, a P/E/G ratio of 1.35 and a beta of 0.
42. Novo Nordisk A/S has a 1 year low of $86.96 and a 1 year high of $148.
15. The business’s fifty day moving average is $132.30 and its two-hundred day moving average is $133.
14. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.
75 and a current ratio of 0.94. Novo Nordisk A/S Cuts Dividend The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th.
Shareholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. This represents a yield of 0.
7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.
83%. Analysts Set New Price Targets NVO has been the subject of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.
00 price objective on shares of Novo Nordisk A/S in a research report on Monday, September 16th. Argus upped their target price on Novo Nordisk A/S from $125.00 to $160.
00 and gave the stock a “buy” rating in a research report on Monday, June 10th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 18th.
The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price for the company.
Finally, BMO Capital Markets cut their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th.
One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and an average price target of $145.17.
Get Our Latest Stock Report on NVO Novo Nordisk A/S Company Profile ( Free Report ) Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. Recommended Stories Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Novo Nordisk A/S ( NYSE:NVO – Free Report ). Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter .
.
